EORTC Risk Tables for Stage Ta T1 Bladder Cancer

(SBC – superficial bladder cancer)


 Bladder Cancer Risk Calculator
 

"; // echo "Tumours: " . $tum_n . "
"; // echo "Diameter: " . $tum_d . "
"; // echo "Recurrnce: " . $tum_r . "
"; // echo "Category: " . $tum_c . "
"; // echo "CIS: " . $tum_s . "
"; // echo "Grade: " . $tum_g . "
"; if ($tum_n==1) { $rec_1 = 0; $pro_1 = 0; } else if ($tum_n==2) { $rec_1 = 3; $pro_1 = 3; } else if ($tum_n==3) { $rec_1 = 6; $pro_1 = 3; } else { $rec_1 = 0; $pro_1 = 0; } if ($tum_d==1) { $rec_2 = 0; $pro_2 = 0; } else if ($tum_d==2) { $rec_2 = 3; $pro_2 = 3; } else { $rec_2 = 0; $pro_2 = 0; } if ($tum_r==1) { $rec_3 = 0; $pro_3 = 0; } else if ($tum_r==2) { $rec_3 = 2; $pro_3 = 2; } else if ($tum_r==3) { $rec_3 = 4; $pro_3 = 2; } else { $rec_3 = 0; $pro_3 = 0; } if ($tum_c==1) { $rec_4 = 0; $pro_4 = 0; } else if ($tum_c==2) { $rec_4 = 1; $pro_4 = 4; } else { $rec_4 = 0; $pro_4 = 0; } if ($tum_s==1) { $rec_5 = 0; $pro_5 = 0; } else if ($tum_s==2) { $rec_5 = 1; $pro_5 = 6; } else { $rec_5 = 0; $pro_5 = 0; } if ($tum_g==1) { $rec_6 = 0; $pro_6 = 0; } else if ($tum_g==2) { $rec_6 = 1; $pro_6 = 0; } else if ($tum_g==3) { $rec_6 = 2; $pro_6 = 5; } else { $rec_6 = 0; $pro_6 = 0; } $rec_total = $rec_1+$rec_2+$rec_3+$rec_4+$rec_5+$rec_6; $pro_total = $pro_1+$pro_2+$pro_3+$pro_4+$pro_5+$pro_6; //echo ""; echo ""; echo ""; echo ""; if ($rec_total==0) { $pr_1 = "15% (10-19%)"; $pr_5 = "31% (24-37%)"; $pr_r = "#33cc00"; $pr_c = "bladgreen"; } else if ($rec_total>0 and $rec_total<5) { $pr_1 = "24% (21-26%)"; $pr_5 = "46% (42-49%)"; $pr_r = "#ff6600"; $pr_c = "bladorange"; } else if ($rec_total>4 and $rec_total<10){ $pr_1 = "38% (35-41%)"; $pr_5 = "62% (58-65%)"; $pr_r = "#ff0033"; $pr_c = "bladred"; } else if ($rec_total>9 and $rec_total<18){ $pr_1 = "61% (55-67%)"; $pr_5 = "78% (73-84%)"; $pr_r = "#ff0033"; $pr_c = "bladred"; } else { $pr_1 = "N/A"; $pr_5 = "N/A"; $pr_r = ""; } if ($pro_total==0) { $pp_1 = "0.2% (0-0.7%)"; $pp_5 = "0.8% (0-1.7%)"; $pp_r = "#33cc00"; $pp_c = "bladgreen"; } else if ($pro_total>1 and $pro_total<7) { $pp_1 = "1% (0.4-1.6%)"; $pp_5 = "6% (5-8%)"; $pp_r = "#ff6600"; $pp_c = "bladorange"; } else if ($pro_total>6 and $pro_total<14){ $pp_1 = "5% (4-7%)"; $pp_5 = "17% (14-20%)"; $pp_r = "#ff0033"; $pp_c = "bladred"; } else if ($pro_total>13 and $pro_total<24){ $pp_1 = "17% (10-24%)"; $pp_5 = "45% (35-55%)"; $pp_r = "#ff0033"; $pp_c = "bladred"; } else { $pp_1 = "N/A"; $pp_5 = "N/A"; $pp_r = ""; } echo ""; echo ""; echo ""; echo ""; echo ""; } ?>
";}?>Number of tumours > ";}?>Single
> 2 - 7
> 8 and more
";}?>Tumour diameter > ";}?>Less than 3cm
> 3cm and more
";}?>Prior recurrence rate > ";}?>Primary tumour
> 1 or less recurrence/year
> 2 or more recurrence/year
";}?>Category > ";}?>Ta
> T1
";}?>CIS > ";}?>No
> Yes
";}?>Grade > ";}?>G1
> G2
> G3
   
 
Recurrence score:$rec_total
Progression score:$pro_total
Probability of: at 1 yr at 5 yr
- Recurrence$pr_1$pr_5
- Progression$pp_1$pp_5
Green - Low risk  | Orange - Intermediate risk  | Red - High risk
Reference: Sylvester RJ, van der Meijden APM, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DWW, Kurth KH. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from 7 EORTC trials. European Urology 49: 466-477, 2006.
Za zgodą prof. Oosterlinck`a, with agreement of prof. Oosterlinck
© 2008-2012 Rozanski Marek, Bialeta Artur, MD, FEBU